Bio-Rad Laboratories, Inc. (NYSE:BIO) – Analysts at Jefferies Group lowered their Q3 2017 EPS estimates for shares of Bio-Rad Laboratories in a research note issued on Friday. Jefferies Group analyst B. Couillard now expects that the medical research company will post earnings per share of $0.39 for the quarter, down from their previous estimate of $0.50. Jefferies Group has a “Buy” rating and a $275.00 price objective on the stock. Jefferies Group also issued estimates for Bio-Rad Laboratories’ Q4 2017 earnings at $1.62 EPS, Q1 2018 earnings at $1.04 EPS, Q3 2018 earnings at $1.07 EPS and Q4 2018 earnings at $1.31 EPS.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, May 4th. The medical research company reported $0.41 EPS for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.14. The firm had revenue of $500.05 million during the quarter, compared to analysts’ expectations of $477.76 million. Bio-Rad Laboratories had a return on equity of 3.15% and a net margin of 0.73%. The company’s quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.42 EPS.

COPYRIGHT VIOLATION WARNING: This story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/07/bio-rad-laboratories-inc-forecasted-to-post-q3-2017-earnings-of-0-39-per-share-nysebio.html.

Several other equities research analysts have also recently commented on BIO. TheStreet cut Bio-Rad Laboratories from a “b” rating to a “c+” rating in a report on Thursday. Wells Fargo & Company started coverage on Bio-Rad Laboratories in a research note on Thursday, July 13th. They set an “outperform” rating and a $250.00 target price for the company. BidaskClub cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, June 14th. Zacks Investment Research cut Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Finally, Deutsche Bank AG raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating and cut their target price for the stock from $220.00 to $195.00 in a research note on Wednesday, June 28th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Bio-Rad Laboratories has an average rating of “Buy” and a consensus price target of $228.80.

Bio-Rad Laboratories (NYSE:BIO) opened at 227.31 on Monday. The company’s 50-day moving average price is $228.57 and its 200-day moving average price is $210.72. The stock has a market cap of $6.73 billion, a PE ratio of 241.31 and a beta of 0.91. Bio-Rad Laboratories has a 12-month low of $143.39 and a 12-month high of $239.91.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BIO. BlackRock Inc. raised its position in Bio-Rad Laboratories by 9,953.4% in the first quarter. BlackRock Inc. now owns 1,733,111 shares of the medical research company’s stock valued at $345,478,000 after buying an additional 1,715,872 shares in the last quarter. Vanguard Group Inc. raised its position in Bio-Rad Laboratories by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,673,274 shares of the medical research company’s stock valued at $333,550,000 after buying an additional 58,774 shares in the last quarter. TimesSquare Capital Management LLC raised its position in Bio-Rad Laboratories by 17.2% in the first quarter. TimesSquare Capital Management LLC now owns 611,700 shares of the medical research company’s stock valued at $121,936,000 after buying an additional 89,800 shares in the last quarter. Alliancebernstein L.P. raised its position in Bio-Rad Laboratories by 1.7% in the first quarter. Alliancebernstein L.P. now owns 335,197 shares of the medical research company’s stock valued at $66,818,000 after buying an additional 5,647 shares in the last quarter. Finally, Fisher Asset Management LLC raised its position in Bio-Rad Laboratories by 1.9% in the second quarter. Fisher Asset Management LLC now owns 279,589 shares of the medical research company’s stock valued at $63,274,000 after buying an additional 5,233 shares in the last quarter. Institutional investors and hedge funds own 63.73% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Earnings History and Estimates for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.